ABUS vs MTD · P/E 5.4, rev $6.2M vs P/E 27, rev $3.87B
Arbutus Biopharma Corp (ABUS) versus Mettler-Toledo International Inc (MTD) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Mettler-Toledo International Inc (MTD) is a diagnostics & research company listed on NYSE.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported MTD revenue for 2024-12-31 was $3.87B. Net income was $863.1M. Revenue was up 2.2% from 2023-12-31 to 2024-12-31. MTD currently screens at market cap $23.20B and trailing P/E 26.9.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. MTD currently screens at market cap $23.20B and trailing P/E 26.9.
Not investment advice. Open the ABUS and MTD stock pages for the full models.
Not investment advice.